Scarica l'app Stockscreener
11.62
3.17%
-0.38
Dopo l'orario di chiusura:
11.62
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Will Intellia Therapeutics Inc. stock reach Wall Street targets2025 Biggest Moves & Daily Profit Maximizing Tips - mfd.ru
Should you avoid Intellia Therapeutics Inc. stock right nowJuly 2025 Selloffs & AI Powered Market Entry Ideas - baoquankhu1.vn
A Look At Intellia Therapeutics (NTLA) Valuation After FDA Lifts Clinical Hold On Key Phase 3 Trial - Sahm
Gene Editing Market Growth in Future Scope 2026-2033| CRISPR - openPR.com
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy? - AOL.com
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy? - The Motley Fool
Intellia Therapeutics (NTLA) Awards Inducement Grants to New Emp - GuruFocus
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Therapeutics, Inc. $NTLA Shares Bought by IQ EQ FUND MANAGEMENT IRELAND Ltd - MarketBeat
Best Gene-Editing Stocks of 2026: Are They Right for Your Portfolio? - The Motley Fool
The Best Biotech Stocks to Buy - Morningstar
Intellia Therapeutics: 2 Major Catalysts Will Determine Stock Trajectory In 2026 (NTLA) - Seeking Alpha
Notable Two Hundred Day Moving Average CrossNTLA - Nasdaq
Intellia Therapeutics Receives Key Regulatory Clearance for Clinical Trial - AD HOC NEWS
Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN
Intellia Therapeutics (NTLA) Price Target Increased by 35.10% to 23.94 - Nasdaq
The Technical Signals Behind (NTLA) That Institutions Follow - Stock Traders Daily
Intellia Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Benchmark - Investor's Business Daily
FDA Clears Intellia Phase 3 ATTRv PN Trial Lifting Key Overhang - Sahm
FDA Lifts Hold On Intellia Trial Refocusing Attention On Valuation Upside - Yahoo Finance
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Clinical Hold On Key Phase 3 Trial - Yahoo Finance
FDA Lifts MAGNITUDE-2 Hold Refocusing Intellia’s ATTR Value Story - Sahm
Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal - Finviz
Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail
The week in pharma: action, reaction and insight – week to January 30, 2026 - The Pharma Letter
Travel Stocks: Is Intellia Therapeutics Inc a top pick in the sectorRecession Risk & Daily Entry Point Trade Alerts - baoquankhu1.vn
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Hold On MAGNITUDE-2 Trial - Sahm
Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE - RTTNews
Intellia’s NTLA-2001 Hits Key Milestone in ATTR Gene-Editing Trial, Raising the Stakes in Amyloidosis - TipRanks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA) and Viridian Therapeutics (VRDN) - The Globe and Mail
Why Intellia Therapeutics (NTLA) Is Down 12.6% After FDA Lifts Hold On Key CRISPR Trial - Sahm
FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials - NeurologyLive
Breaking Down Intellia Therapeutics: 11 Analysts Share Their Views - Benzinga
Intellia Therapeutics (NASDAQ:NTLA) Trading Down 6.6%Time to Sell? - MarketBeat
NTLA Stock Rating Maintained and Price Target Raised by HC Wainw - GuruFocus
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold - Finviz
Y Intercept Hong Kong Ltd Makes New $2.37 Million Investment in Intellia Therapeutics, Inc. $NTLA - MarketBeat
H.C. Wainwright raises Intellia Therapeutics stock price target on clinical hold lift - Investing.com Canada
Brokers Offer Predictions for NTLA FY2030 Earnings - MarketBeat
Intellia Gets Nex-z Phase III Study Boost After FDA Lifts Clinical Hold - Citeline News & Insights
Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? - Yahoo Finance
Intellia Therapeutics - The Pharma Letter
FDA Clears MAGNITUDE-2 Hold Leaving Intellia Cardiomyopathy Questions Open - Yahoo Finance
Intellia Therapeutics to resume dosing of gene therapy in Phase III trial - Clinical Trials Arena
Intellia gets FDA nod to resume one gene therapy trial after safety pause - ET Pharma
Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug - MSN
Intellia’s nex-z moves ahead, but only for ATTR-PN for now - BioWorld MedTech
FDA Lifts Hold on Intellia's Nexiguran Ziclumeran Program (NTLA) - GuruFocus
Can Intellia Therapeutics Inc. sustain its profitabilityTrend Reversal & Risk Adjusted Buy and Sell Alerts - mfd.ru
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap UpTime to Buy? - MarketBeat
Why Is Intellia Stock Trading Higher Today?Intellia Therapeutics (NASDAQ:NTLA) - Benzinga
Cathie Wood’s ARK Boosts NTLA Shares With Significant Acquisition - StocksToTrade
FDA lifts hold on an Intellia CRISPR drug trial - BioPharma Dive
Intellia shares leap as FDA lifts trial hold - The Pharma Letter
NTLA Stock Jumped 13% Today – What Is The Latest FDA Action All About? - Stocktwits
Intellia Therapeutics Stock (NTLA) Pops as FDA Lifts Safety Freeze on Nerve Disease Trial - TipRanks
Intellia (NTLA) Surges 24% Following FDA Green Light for Phase 3 Study - GuruFocus
Intellia Announces FDA Lift Of Clinical Hold On MAGNITUDE-2 Phase 3 Trial In ATTRv-PN - Nasdaq
Intellia Therapeutics (NTLA) Surges After FDA Lifts Clinical Hol - GuruFocus
FDA Lifts Hold on Intellia’s MAGNITUDE-2 Trial - TipRanks
Intellia Therapeutics (NTLA) Resumes Phase 3 Trial for Hereditar - GuruFocus
Why Intellia Therapeutics Is Rising In Pre-market? - Nasdaq
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):